- Home
- ALXO vs LPSN Comparison
ALXO vs LPSN Comparison
Compare ALXO & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- LPSN
- Stock Information
- Founded
- ALXO 2015
- LPSN 1995
- Country
- ALXO United States
- LPSN United States
- Employees
- ALXO N/A
- LPSN N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- LPSN EDP Services
- Sector
- ALXO Health Care
- LPSN Technology
- Exchange
- ALXO Nasdaq
- LPSN Nasdaq
- Market Cap
- ALXO 76.5M
- LPSN 71.2M
- IPO Year
- ALXO 2020
- LPSN 2000
- Fundamental
- Price
- ALXO $0.55
- LPSN $0.75
- Analyst Decision
- ALXO Strong Buy
- LPSN Hold
- Analyst Count
- ALXO 6
- LPSN 5
- Target Price
- ALXO $4.14
- LPSN $0.98
- AVG Volume (30 Days)
- ALXO 529.8K
- LPSN 1.3M
- Earning Date
- ALXO 05-08-2025
- LPSN 05-07-2025
- Dividend Yield
- ALXO N/A
- LPSN N/A
- EPS Growth
- ALXO N/A
- LPSN N/A
- EPS
- ALXO N/A
- LPSN N/A
- Revenue
- ALXO N/A
- LPSN $312,474,000.00
- Revenue This Year
- ALXO N/A
- LPSN N/A
- Revenue Next Year
- ALXO N/A
- LPSN $29.08
- P/E Ratio
- ALXO N/A
- LPSN N/A
- Revenue Growth
- ALXO N/A
- LPSN N/A
- 52 Week Low
- ALXO $0.46
- LPSN $0.45
- 52 Week High
- ALXO $17.83
- LPSN $2.08
- Technical
- Relative Strength Index (RSI)
- ALXO 37.26
- LPSN 41.50
- Support Level
- ALXO $0.46
- LPSN $0.72
- Resistance Level
- ALXO $0.63
- LPSN $0.82
- Average True Range (ATR)
- ALXO 0.06
- LPSN 0.08
- MACD
- ALXO 0.02
- LPSN 0.01
- Stochastic Oscillator
- ALXO 42.86
- LPSN 56.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.